Upcoming Investor Conferences Announcement
Lifecore Biomedical, Inc. (NASDAQ: LFCR), a prominent player in the contract development and manufacturing organization (CDMO) sector, has announced its participation in two major investor conferences. This is a strategic opportunity for the company to engage with investors and share insights into their operations and growth potential.
Details of the Jefferies Global Healthcare Conference
Corporate Presentation and Meetings
At the Jefferies 2025 Global Healthcare Conference, Lifecore's President and CEO, Paul Josephs, will deliver an important corporate presentation. This event is designed to facilitate investor meetings and discussions around Lifecore's innovative strategies. The conference is set from November 17-20, 2025, with Mr. Josephs scheduled to present on November 18, 2025, from 9:30 to 9:55 a.m. GMT.
Stephens Annual Investment Conference Participation
A Fireside Chat with Management
In addition to the Jefferies conference, Lifecore's management is also slated to participate in the Stephens Annual Investment Conference scheduled from November 18-20, 2025. Mr. Josephs will be a featured speaker in a fireside chat, further showcasing Lifecore's strategic initiatives. This session is expected to provide valuable insights into the company’s vision and operational success, occurring on November 20, 2025, from 9:00 to 9:45 a.m. Central Time.
Webcast Availability
Both the Jefferies presentation and the Stephens fireside chat will be accessible via lifecore's investor website, making it easy for shareholders and potential investors to engage with key information about the company. This accessibility underscores Lifecore's commitment to transparency and investor relations. Replays will be available directly on their site following the events.
About Lifecore Biomedical
Lifecore Biomedical, Inc. prides itself on its extensive capabilities in the development and manufacturing of sterile injectable pharmaceutical products. With over 40 years of expertise, Lifecore is recognized for producing high-quality, injectable-grade hyaluronic acid. This capability positions them as a vital partner for both established and emerging biopharmaceutical companies across various therapeutic areas. Their focus on innovation and excellence aids in bringing groundbreaking products to market.
Contact Information
If you wish to reach out regarding Lifecore's upcoming activities or investor relations, here is the contact information:
Vida Strategic Partners
Stephanie Diaz (Investors)
Phone: 415-675-7401
Email: sdiaz@vidasp.com
Tim Brons (Media)
Phone: 415-675-7402
Email: tbrons@vidasp.com
Ryan D. Lake (CFO)
Lifecore Biomedical
Phone: 952-368-6244
Email: ryan.lake@lifecore.com
Frequently Asked Questions
What is the main focus of Lifecore Biomedical?
Lifecore Biomedical specializes in the contract development and manufacturing of sterile injectable pharmaceutical products, particularly producing injectable-grade hyaluronic acid.
What conferences is Lifecore Biomedical participating in?
Lifecore Biomedical will feature at the Jefferies 2025 Global Healthcare Conference and the Stephens Annual Investment Conference.
When will Lifecore's presentations take place?
The presentation at the Jefferies conference is on November 18, and the fireside chat at the Stephens conference is scheduled for November 20, both in 2025.
How can investors access the conference content?
Investors can access live webcasts of both presentations through Lifecore's investor website, where replays will also be available afterward.
Who can be contacted for investor inquiries?
For investor inquiries, stakeholders can contact Stephanie Diaz at Vida Strategic Partners, or reach out to Ryan D. Lake at Lifecore Biomedical.